Phase 1 Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trials
4 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–4 of 4 trials
Recruiting
Phase 1
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Myasthenia GravisMultiple SclerosisChronic Inflammatory Demyelinating Polyneuropathy
Kite, A Gilead Company52 enrolled3 locationsNCT07304154
Recruiting
Phase 1
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Neuromyelitis Optica Spectrum Disorder (NMOSD)Multiple Sclerosis (MS)Myasthenia Gravis (MG)+3 more
Tongji Hospital6 enrolled1 locationNCT07526493
Recruiting
Phase 1
IVIG vs SCIG in CIDP
Chronic Inflammatory Demyelinating PolyneuropathyCIDPImmunoglobulin Deficiency
Rutgers, The State University of New Jersey20 enrolled1 locationNCT05584631
Not Yet Recruiting
Phase 1
A Phase 1 Open-label, Multiregional, Multicenter, Basket Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy in Participants with Relapsed/Refractory Autoimmune Neurologic Diseases
Myasthenia GravisMultiple SclerosisChronic Inflammatory Demyelinating Polyneuropathy
Kite, A Gilead Company52 enrolled2 locationsACTRN12625001346460